Biotech | August 06, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Subscribe To Our Newsletter & Stay Updated
